Skip to Main Content (Press Enter)

Logo UNINSUBRIA
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNINSUBRIA

|

UNI-FIND

uninsubria.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Pubblicazioni

Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study

Articolo
Data di Pubblicazione:
2022
Abstract:
Background Oral corticosteroid (OCS) dependence among patients with severe eosinophilic asthma can cause adverse outcomes, including adrenal insufficiency. PONENTE's OCS reduction phase showed that, following benralizumab initiation, 91.5% of patients eliminated corticosteroids or achieved a final dosage ≤5 mg·day-1 (median (range) 0.0 (0.0-40.0) mg). Methods The maintenance phase assessed the durability of corticosteroid reduction and further adrenal function recovery. For ~6 months, patients continued benralizumab 30 mg every 8 weeks without corticosteroids or with the final dosage achieved during the reduction phase. Investigators could prescribe corticosteroids for asthma exacerbations or increase daily dosages for asthma control deteriorations. Outcomes included changes in daily OCS dosage, Asthma Control Questionnaire (ACQ)-6 and St George's Respiratory Questionnaire (SGRQ), as well as adrenal status, asthma exacerbations and adverse events. Results 598 patients entered PONENTE; 563 (94.1%) completed the reduction phase and entered the maintenance phase. From the end of reduction to the end of maintenance, the median (range) OCS dosage was unchanged (0.0 (0.0-40.0) mg), 3.2% (n=18/563) of patients experienced daily dosage increases, the mean ACQ-6 score decreased from 1.26 to 1.18 and 84.5% (n=476/563) of patients were exacerbation free. The mean SGRQ improvement (-19.65 points) from baseline to the end of maintenance indicated substantial quality-of-life improvements. Of patients entering the maintenance phase with adrenal insufficiency, 32.4% (n=104/321) demonstrated an improvement in adrenal function. Adverse events were consistent with previous reports. Conclusions Most patients successfully maintained maximal OCS reduction while achieving improved asthma control with few exacerbations and maintaining or recovering adrenal function.
Tipologia CRIS:
Articolo su Rivista
Elenco autori:
Menzies-Gow, A.; Gurnell, M.; Heaney, L. G.; Corren, J.; Bel, E. H.; Maspero, J.; Harrison, T.; Jackson, D. J.; Price, D.; Lugogo, N.; Kreindler, J.; Burden, A.; de Giorgio-Miller, A.; Faison, S.; Padilla, K.; Martin, U. J.; Gil, E. G.; Ardusso, L.; Bazerque, R. F.; Doreski, P. A. C.; Elias, P. C.; Gattolin, G.; Medina, A. C.; Ruiz, X. B.; Salvado, A.; Del Olmo Sansone, R. A.; Wehbe, L.; Verra, F. J. B.; Brusselle, G.; Pilette, C.; Martinot, J. -B.; Antila, M. A.; Blanco, D. C.; Cerci, A.; Cunha, T. M.; Fiss, E.; Franza, L.; Machado, A. S.; De Mattos, W. L. L. D.; Grava, S.; Minamoto, S. E. T.; De Oliveira, C. A.; Cheema, A. S.; Dorscheid, D.; Fera, T. A. E.; Gagnon, R.; Philteos, G.; Sussman, G.; Yang, W. H. -C.; Aguilar, C. D.; Jaller, R.; Jazime, M. L.; Serrano, F. O.; Vanegas, A. C.; Vargas, L. K.; Villegas, M. F.; Hilberg, O.; Nielsen, H. B.; Nielsen, J.; Weinreich, U. M.; Ulrik, C. S.; Adam, S. M.; Deslee, G.; Pegliasco, H.; Pradelli, J.; Roux, P. -M.; Russier, M.; Deckelmann, R.; Eich, A.; Forster, A.; Herth, F.; Kirschner, J.; Kirsten, A. -M.; Schuhmann, M.; Schultz, T. K.; Ludwig-Sengpiel, A.; Teber, I.; Zimmermann, G. S.; Almerigogna, F.; Celi, A.; Paggiaro, P.; D'Amato, M.; Palange, P.; Pirina, P.; Spanevello, A.; Colin, D. D. H.; Hernandez, A. R.; Garcia, E. A. R.; Gonzalez, E. M.; Terrones, R. A. R.; Javier, R. C.; Suarez, J. F. R.; Cheimihska, M.; Cudzik, K.; Olech-Cudzik, A.; Filipek, K.; Golinski, L.; Kwasniewski, A.; Madra-Rogacka, D.; Mroz, R.; Nittner-Marszalska, M.; Pawlukiewicz, M.; Lekarska, P. P.; Pioszczuk, A.; Springer, E.; Swiderska, A.; Zurowska-Gebala, M.; Emelyanov, A. V.; Kurbacheva, O.; Odegova, A.; Peskov, A.; Petrov, D. V.; Rubanik, T. V.; Vasilev, M.; Vershinina, M.; Barcala, F. J. G.; Blanco, V. R.; Fernandez, A. M. P.; Fernandez, C. G.; Garcia, J. M. I.; Munoz, A. V. A.; Ramos, C. C.; Sanz, C. C.; Bjermer, L.; Chen, C. -Y.; Fang, W. -F.; Hang, L. -W.; Hsu, J. -Y.; Kuo, H. -P.; Lee, K. -Y.; Shen, S. -Y.; Sheu, C. -C.; Gore, R.; Saralaya, D.; Alpizar, S. A.; Bansal, S.; Ismail, H.; Kaelin, T. D.; Koura, F.; Lee, M. D.; Maddipati, V.; Malur, A.; Mcevoy, C. E.; Mehta, H.; Mohan, A.; Moore, W. C.; Krings, J.; Pippins, A.; Deaton, I.; Hmieleski, B.; Field, P.; Reibman, J.; Siri, D. D.; Sumino, K.; Swenson, C.; Tilley, S. L.; Villareal, M.
Autori di Ateneo:
Centro di ricerca sulle Malattie Croniche
SPANEVELLO ANTONIO
Link alla scheda completa:
https://irinsubria.uninsubria.it/handle/11383/2150880
Link al Full Text:
https://irinsubria.uninsubria.it//retrieve/handle/11383/2150880/210060/Adrenal-function-recovery-after-durable-oral-corticosteroid-sparing-with-benralizumab-in-the-PONENTE-studyEuropean-Respiratory-Journal.pdf
Pubblicato in:
EUROPEAN RESPIRATORY JOURNAL
Journal
  • Accessibilità
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.2.0